TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17136950

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 6 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Paroxetine (un-blinded) for 3 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 28
Study: 11995818

Group type: EXPERIMENTAL
Intervention: Local implantation of bucladesine-loaded biodegradable polymeric sustained release (bcl-SR) pellets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic chemotherapy with six i.v. infusions of fotémustine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tumor resection only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Systemic fotémustine + local implantation of bcl-SR pellets
Number of subjects: 40
Study: 10446490

Group type: EXPERIMENTAL
Intervention: KRN8602 (15 mg/m2/day for 5 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Daunorubicin (40 mg/m2/day for 3 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Number of subjects: 58
Study: 7493059

Group type: EXPERIMENTAL
Intervention: Oxygent® (1.35 g PFC/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxygent® (1.8 g PFC/kg)
Number of subjects: 30
Study: 2033427

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: MOPP chemotherapy
Number of subjects: 136
Study: 7471802

Group type: EXPERIMENTAL
Intervention: Halcinonide cream (0.025%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 79

Group type: COMPARATOR
Intervention: Halcinonide cream (0.025%) and Placebo cream
Number of subjects: 79
Study: 31961926

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based chemotherapy induction
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Rituximab-based chemotherapy induction
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Overall analysis of bSUVmax
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Assessment of bSUVmax and bSUVrange
Number of subjects: 549
Study: 30862659

Group type: EXPERIMENTAL
Intervention: Culturally adapted family‐model DSME (adapted DSME)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard DSME
Number of subjects: 221
Study: 29854262

Group type: EXPERIMENTAL
Intervention: Independent non-lattice fragments
Number of subjects: 32241

Group type: EXPERIMENTAL
Intervention: Independent lattice fragments
Number of subjects: 32241

Group type: EXPERIMENTAL
Intervention: Randomized relational error detection methods
Number of subjects: 32241

Group type: EXPERIMENTAL
Intervention: Lattice vs. non-lattice fragments
Number of subjects: 32241
Study: 25670836

Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Outside-in (OI) technique
Number of subjects: 70
Study: 24576148

Group type: EXPERIMENTAL
Intervention: PSYMEPHY treatment (6-week interdisciplinary treatment)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (standard pharmacologic care)
Number of subjects: 110
Study: 22860637

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 3 mg AA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 15 mg AA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 30 mg AA
Number of subjects: 70
Study: 19398279

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429
Study: 17516992

Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 45 days (Group IV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 90 days (Group V)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice a day for more than 1 year (Group III)
Number of subjects: 84
Study: 15498622

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/d, at least one i.v. dose)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ceftriaxone +/‐ azithromycin +/‐ metronidazole (control group)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 221
Study: 11465936

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (500 mg b.i.d.)
Number of subjects: 289

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 289
Study: 9496494

Group type: EXPERIMENTAL
Intervention: PEG‐ELS
Number of subjects: 26

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 26
Study: 7990030

Group type: EXPERIMENTAL
Intervention: Experimental trial (lactic acidosis)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 6
Study: 2916871

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg single dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clonidine (initial dose of 0.1 mg with hourly doses of 0.1 mg)
Number of subjects: 51
Study: 5015049

Group type: EXPERIMENTAL
Intervention: Selective vagotomy without drainage procedure
Number of subjects: 0
Study: 30412905

Group type: COMPARATOR
Intervention: Glucose (75 g, GLU) alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Non-fat dairy milk (MILK)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Whey (WHEY)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Casein (CASEIN)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dairy trials (MILK, WHEY, CASEIN)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dairy milk (MILK)
Number of subjects: 23
Study: 29140134

Group type: EXPERIMENTAL
Intervention: Recovery station access for 30 minutes post-exercise
Number of subjects: 127
Study: 24725465

Group type: EXPERIMENTAL
Intervention: PCA with remifentanil and diclofenac (50 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Pethidine (2 mg/kg i.m.) and midazolam (7.5 mg)
Number of subjects: 76
Study: 23547631

Group type: EXPERIMENTAL
Intervention: CPAP (7 mbar) with supplemental oxygen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Supplemental oxygen only
Number of subjects: 18
Study: 21061414

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention consisting of twelve group-based sessions
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 170
Study: 18787094

Group type: EXPERIMENTAL
Intervention: Fluid Replacement (FR) trial
Number of subjects: 13

Group type: COMPARATOR
Intervention: No-Fluid Replacement (NFR) trial
Number of subjects: 13
Study: 16567357

Group type: EXPERIMENTAL
Intervention: Abatacept + DMARDs
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo + DMARDs
Number of subjects: 391
Study: 14596626

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (Estrostep, containing norethisterone acetate 1mg and ethinylestradiol [20, 30, 35 mg])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11024603

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1 mg kg(‐1) bolus followed by 40 microg kg(‐1) min(‐1) for 4 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 6
Study: 8970269

Group type: EXPERIMENTAL
Intervention: DAB486IL-2
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1307344

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional intramuscular analgesia
Number of subjects: 10
Study: 6692110

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Ampicillin + Metronidazole
Number of subjects: 209
Study: 31094783

Group type: EXPERIMENTAL
Intervention: 80% intraoperative oxygen
Number of subjects: 4702

Group type: COMPARATOR
Intervention: 30% intraoperative oxygen
Number of subjects: 4702
Study: 29420518

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Gabapentin 450 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Amaranth dragees (Control)
Number of subjects: 125
Study: 27137822

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laser and magnetostimulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnetostimulation
Number of subjects: 120
Study: 24481862

Group type: EXPERIMENTAL
Intervention: Peer advisor intervention (nondirective counseling style)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Peer advisor intervention (specific goal setting)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Video assessment tool
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Questionnaire-derived measures
Number of subjects: 102
Study: 22317944

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (200 mg and 400 mg respectively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg) and placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg) and placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 60
Study: 20183736

Group type: EXPERIMENTAL
Intervention: Hypnosis/therapeutic suggestion with standard sedation dose of intravenous anesthetic
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (listened to music)
Number of subjects: 100
Study: 18568696

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment based on home BP monitoring
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care with office visits
Number of subjects: 236
Study: 16423099

Group type: EXPERIMENTAL
Intervention: Curricular intervention (6-week course on communication and clinical reasoning)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 12523216

Group type: EXPERIMENTAL
Intervention: Probiotics for acute viral gastroenteritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics for systemic diseases (e.g., atopic dermatitis)
Number of subjects: 0
Study: 9892780

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RM-GIC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 33
Study: 8834648

Group type: EXPERIMENTAL
Intervention: rHuEPO (EPO group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (No-EPO group)
Number of subjects: 20
Study: 16296713

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 78
Study: 6111330

Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg (2 weeks administration, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (0.2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous practolol (1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (0.2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous SL 75212 (0.15 and 0.6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 100 and 500 μg/ml added to whole blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lignocaine 5 μg/ml added to whole blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol at 1000 ng/ml or less
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol 5 and 500 μg/ml and 5 mg/ml
Number of subjects: 0
Study: 30793920

Group type: EXPERIMENTAL
Intervention: ¼ dose reduction fluoroscopy
Number of subjects: 94
Study: 28202072

Group type: EXPERIMENTAL
Intervention: Mini implants (MI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional implants (CI)
Number of subjects: 46
Study: 25823790

Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressor (stress induction)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (control procedure)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 400 mg spironolactone (MR availability)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (MR blocked)
Number of subjects: 101
Study: 23731690

Group type: EXPERIMENTAL
Intervention: Direct application of basic fibroblast growth factor (bFGF)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Edge approximation alone
Number of subjects: 58

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 58
Study: 21247457

Group type: EXPERIMENTAL
Intervention: AA genotype in Bai Ku Yao
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: AA genotype in Han
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Genotypes in Bai Ku Yao and Han
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Multivariate linear regression analysis
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Serum lipid parameters
Number of subjects: 1323
Study: 19577021

Group type: EXPERIMENTAL
Intervention: Salbutamol (sustained released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 17038059

Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction Power (CAPB) with three different modes of brushing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual toothbrush Butler GUM 311 (CTB)
Number of subjects: 30
Study: 14642054

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Medication treatment alone
Number of subjects: 320
Study: 10986526

Group type: EXPERIMENTAL
Intervention: Supportive educational nursing intervention
Number of subjects: 179

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 179
Study: 9308061

Group type: EXPERIMENTAL
Intervention: Propofol infusion anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopentone induction and isoflurane maintenance
Number of subjects: 30
Study: 8418875

Group type: EXPERIMENTAL
Intervention: Unilateral cleft patients treated with presurgical orthopedics
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Unilateral cleft patients not treated with presurgical orthopedics
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bilateral cleft patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cleft patients (both unilateral and bilateral)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Noncleft subjects
Number of subjects: 103
Study: 3549794

Group type: EXPERIMENTAL
Intervention: Citric acid pH 0.6 for 3 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 12
Study: 30261959

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 10732

Group type: COMPARATOR
Intervention: High thrombus burden
Number of subjects: 10732
Study: 28138830

Group type: EXPERIMENTAL
Intervention: Suppression group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple guilty group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brainwave-based CIT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: aIAT
Number of subjects: 0
Study: 24331637

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99
Study: 23318497

Group type: EXPERIMENTAL
Intervention: Exercise with Acipimox (Aci) administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exercise without Acipimox (placebo)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acipimox (Aci) administration post-exercise
Number of subjects: 18
Study: 20692745

Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation approach
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation approach
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both patient groups
Number of subjects: 61
Study: 18259012

Group type: EXPERIMENTAL
Intervention: Norepinephrine transporter inhibition with 8 mg reboxetine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17020983

Group type: COMPARATOR
Intervention: Paclitaxel alone (175 mg/m(2)/i.v.)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 days followed by paclitaxel
Number of subjects: 27
Study: 15284389

Group type: EXPERIMENTAL
Intervention: Soy protein (S) - 26.6 +/- 4.5 g protein, 44.4 +/- 7.5 mg isoflavones/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soy + probiotics (S+P) - 10(9) colony-forming units Lactobacillus acidophilus DDS+1 and Bifidobacterium longum, 15-30 mg fructooligosaccharide/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Milk protein (M) - 26.6 +/- 4.5 g protein/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Milk + probiotics (M+P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (C) - Women without a history of breast cancer
Number of subjects: 40
Study: 11500187

Group type: EXPERIMENTAL
Intervention: Fenofibrate plus folic acid, vitamin B6 and B12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenofibrate plus placebo
Number of subjects: 0
Study: 10197170

Group type: EXPERIMENTAL
Intervention: Synovial fluid markers (aggrecan fragments, matrix metalloproteinases-1 and -3, tissue inhibitor of metalloproteinases-1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Serum markers (keratan sulfate)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Urine markers (type I collagen N-telopeptide cross-links)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Joint fluid aggrecan fragment concentrations
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-3 concentrations
Number of subjects: 52
Study: 8119015

Group type: EXPERIMENTAL
Intervention: Intramedullary instrumentation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Extramedullary instrumentation
Number of subjects: 26
Study: 3277506

Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (2 g in 60 mL nightly retention enema for 8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (60 mL nightly retention enema for 8 weeks)
Number of subjects: 25
Study: 29091515

Group type: EXPERIMENTAL
Intervention: Function-related goals related to recreation and leisure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Function-related goals related to walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balance-related goals
Number of subjects: 0
Study: 28817199

Group type: EXPERIMENTAL
Intervention: Biological products for the treatment of rheumatoid arthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/methotrexate control
Number of subjects: 0
Study: 26225130

Group type: EXPERIMENTAL
Intervention: HMB supplementation (3×1 gHMB·day(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administration (PLA)
Number of subjects: 16
Study: 24188672

Group type: EXPERIMENTAL
Intervention: Immunotherapy (M-FP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 21344046

Group type: EXPERIMENTAL
Intervention: Combined intervention of CBT for insomnia and imagery rehearsal therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care comparison group
Number of subjects: 22
Study: 18445705

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: etravirine 400 mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: moxifloxacin 400 mg once daily (positive control)
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 16480472

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 microg) added to hyperbaric bupivacaine (2.0 ml of 0.5%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (2.0 ml of 0.5%) with saline (0.4 ml)
Number of subjects: 40
Study: 14603404

Group type: EXPERIMENTAL
Intervention: Live presentation mode (n=11)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Small-group 2-hour virtual (n=8)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Large-group 2-hour virtual (n=69)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Large-group virtual in four half-hour sessions across 4 days (n=37)
Number of subjects: 125
Study: 11272605

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9093498

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy from a trained community nurse
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual from general practitioner
Number of subjects: 70
Study: 8458463

Group type: EXPERIMENTAL
Intervention: 7-day protocol (Tripteriline 0.1, administered daily for 7 days starting on cycle day 2)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Long protocol (Tripteriline 3.75 mg, administered on cycle day 2)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 7-day protocol
Number of subjects: 182

Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 182
Study: 2427857

Group type: EXPERIMENTAL
Intervention: Celiprolol (0.07 and 0.14 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol (0.07 mg/kg)
Number of subjects: 18
Study: 28616720

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy of the tumor bed (SRT-TB)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 59
Study: 27502721

Group type: EXPERIMENTAL
Intervention: Full (unadjusted) dose of chemotherapy
Number of subjects: 555

Group type: COMPARATOR
Intervention: Adjusted BSA chemotherapy
Number of subjects: 555

Group type: COMPARATOR
Intervention: Non-obese patients
Number of subjects: 555

Group type: COMPARATOR
Intervention: Obese patients receiving full-dose chemotherapy
Number of subjects: 555

Group type: COMPARATOR
Intervention: Obese patients receiving adjusted BSA chemotherapy
Number of subjects: 555
Study: 24060107

Group type: EXPERIMENTAL
Intervention: tDCS alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS combined with sertraline
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 120
Study: 22052870

Group type: EXPERIMENTAL
Intervention: External lateral stabilization (LS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Running without arm swing
Number of subjects: 0